Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Phio Pharmaceuticals Corp. (PHIO)
USD0.89
-0.14 (-13.58%)
US NASDAQ Healthcare Biotechnology
Address
411 Swedeland Road 19406
Marlborough, PA, US
Marlborough, PA, US
CEO
Robert L. Bitterman
Website
phiopharma.com
IPO
2012-05-10
CIK 1533040 ISIN US71880W5013
Also trades on
NASDAQ Capital Market · PHIO (USD)
NASDAQ Capital Market · PHIOW (USD)
Description
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.89
-0.14 (-13.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
157.3K
Beta
0.81
Float Shares
10.38M
Free Float %
89.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.89% | -1.82% | -14.96% | +4.85% | -9.24% | +2.86% | -40.98% | -97.18% | -99.51% | -100.00% | -99.66% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.89
DCF (Unlevered)
3.45
+287.3%
DCF (Levered)
3.51
+294.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-6.01
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-59.3% Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,929.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+659.9% Q1'26: +169.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2018 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 EPS Ana. |
Dec 2027 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
34.0K
est: 34.0K (+0.0%)
|
19.0K
est: 19.0K (+0.0%)
|
138.0K
est: 100.0K (+38.0%)
|
—
est: 50.00M (-100.0%)
|
—
est: 50.00M (-100.0%)
|
—
est: 75.00M (-100.0%)
|
—
est: 50.00M (-100.0%)
|
—
est: 75.00M (-100.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-10.16M
|
-8.96M
|
-7.28M
|
-13.44M
|
-11.39M
|
-10.64M
|
-7.39M
|
-9.22M
|
—
— – —
|
—
— – —
|
| EBIT |
-10.24M
|
-9.02M
|
-7.36M
|
-13.51M
|
-11.46M
|
-10.83M
|
-7.39M
|
-9.22M
|
—
— – —
|
—
— – —
|
| Net Income |
-10.22M
est: -982.29B (+100.0%)
|
-8.99M
est: -547.27B (+100.0%)
|
-7.36M
est: -84.66B (+100.0%)
|
-13.29M
est: -944.01M (+98.6%)
|
-11.48M
est: -773.92M (+98.5%)
|
-10.83M
est: -443.66M (+97.6%)
|
-7.15M
est: -51.10M (+86.0%)
|
-8.70M
est: -9.36M (+7.1%)
|
-8.23M
-8.35M – -8.05M
+12.1% YoY
|
-5.15M
-6.08M – -4.21M
+37.5% YoY
|
| SGA |
3.35M
|
3.62M
|
3.18M
|
4.63M
|
4.45M
|
4.29M
|
3.74M
|
4.60M
|
—
— – —
|
—
— – —
|
| EPS |
-93,029.39
est: -124,740.00 (+25.4%)
|
-79,282.81
est: -69,498.00 (-14.1%)
|
-6,218.35
est: -10,751.40 (+42.2%)
|
-111.32
est: -119.88 (+7.1%)
|
-89.61
est: -98.28 (+8.8%)
|
-46.87
est: -56.34 (+16.8%)
|
-0.91
est: -8.54 (+89.3%)
|
-1.45
est: -1.57 (+7.3%)
|
-1.38
-1.39 – -1.35
+12.1% YoY
|
-0.86
-1.02 – -0.70
+37.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.71M
OE per share TTM
-1.43
Owner's Yield
-85.33%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
9,952.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13G/A | 3.39M | 4.99% | — | 3.39M | — | 3.39M | IA, PN | Ontario Canada | 2016-02-05 | ↗ |
| 2 | Daniel B. Asher | 811.8K | 5.70% | — | 811.8K | — | 811.8K | HC, IN | United States of America | 2022-02-11 | ↗ |
| 3 | Intracoastal Capital LLC | 811.8K | 5.70% | — | 811.8K | — | 811.8K | OO | Delaware | 2022-02-11 | ↗ |
| 4 | Empery Asset Management, LP | 789.1K | 4.99% | — | 789.1K | — | — | PN | Delaware | 2022-01-20 | ↗ |
| 5 | Martin D. Hoe | 789.1K | 4.99% | — | 789.1K | — | — | IN | United States | 2022-01-20 | ↗ |
| 6 | Ryan M. Lane | 789.1K | 4.99% | — | 789.1K | — | — | IN | United States | 2022-01-20 | ↗ |
| 7 | (2) | 446.4K | 5.11% | 446.4K | — | 446.4K | — | CO | Delaware | 2017-01-12 | ↗ |
| 8 | Alex Noah Investors, Inc. | 428.6K | 9.99% | — | 428.6K | — | — | CO | Illinois | 2018-04-13 | ↗ |
| 9 | Jonathan I. Cope | 428.6K | 9.99% | — | 428.6K | — | — | IN | United States | 2018-04-13 | ↗ |
| 10 | Joshua B. Scheinfeld | 428.6K | 9.99% | — | 428.6K | — | — | IN | United States | 2018-04-13 | ↗ |
| 11 | Lincoln Park Capital Fund, LLC | 428.6K | 9.99% | — | 428.6K | — | — | OO | Illinois | 2018-04-13 | ↗ |
| 12 | Lincoln Park Capital, LLC | 428.6K | 9.99% | — | 428.6K | — | — | OO | Illinois | 2018-04-13 | ↗ |
| 13 | Rockledge Capital Corporation | 428.6K | 9.99% | — | 428.6K | — | — | CO | Texas | 2018-04-13 | ↗ |
| 14 | CVI Investments, Inc. | 428.3K | 9.30% | — | 428.3K | — | 428.3K | CO | Cayman Islands | 2020-04-09 | ↗ |
| 15 | Anson FundsManagement LP | 377.7K | 8.90% | — | 377.7K | — | 377.7K | IA, PN | Texas | 2018-04-18 | ↗ |
| 16 | Sabby Volatility Warrant Master Fund, Ltd. | 377.7K | 8.87% | — | 377.7K | — | 377.7K | CO | USA | 2018-04-11 | ↗ |
| 17 | Armistice Capital Master Fund Ltd. | 240.6K | 4.99% | — | 240.6K | — | 240.6K | CO | Delaware | 2020-04-08 | ↗ |
| 18 | Armistice Capital, LLC | 240.6K | 4.99% | — | 240.6K | — | 240.6K | IA, OO | Delaware | 2020-04-08 | ↗ |
| 19 | Steven Boyd | 240.6K | 4.99% | — | 240.6K | — | 240.6K | HC, IN | Delaware | 2020-04-08 | ↗ |
| 20 | Heights Capital Management, Inc. | 228.9K | 4.00% | — | 228.9K | — | 228.9K | CO | Cayman Islands | 2021-02-16 | ↗ |
| 21 | Mitchell P. Kopin | 188.3K | 9.99% | — | 188.3K | — | 188.3K | HC, IN | United States of America | 2020-02-13 | ↗ |
| 22 | OPKO Health, Inc. | 66.9K | 2.80% | 66.9K | — | 66.9K | — | CO | Delaware | 2018-02-12 | ↗ |
| 23 | KEVIN C. TANG | — | 0.00% | — | — | — | — | IN | UNITED STATES | 2016-02-16 | ↗ |
| 24 | TANG CAPITAL MANAGEMENT, LLC | — | 0.00% | — | — | — | — | OO | DELAWARE | 2016-02-16 | ↗ |
| 25 | TANG CAPITAL PARTNERS, LP | — | 0.00% | — | — | — | — | PN | DELAWARE | 2016-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 102.3K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
242.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+242,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-05 | Lockshin Curtis | Director | A-Award | A | Common Stock, $.0001 par value | 16,600 | 0.00 | — | 35,155 | D | ↗ |
| 2026-02-05 | Freeman Jonathan E | Director | A-Award | A | Common Stock, $.0001 par value | 16,600 | 0.00 | — | 32,655 | D | ↗ |
| 2026-02-05 | Deming David H | Director | A-Award | A | Common Stock, $.0001 par value | 23,800 | 0.00 | — | 37,800 | D | ↗ |
| 2026-02-05 | Carson Lisa Cabott | Officer | A-Award | A | Common Stock, $.0001 par value | 47,000 | 0.00 | — | 94,000 | D | ↗ |
| 2026-02-05 | Bitterman Robert J | Director / Officer | A-Award | A | Common Stock, $.0001 par value | 120,000 | 0.00 | — | 411,421 | D | ↗ |
| 2026-02-05 | BRADFORD PATRICIA A | Director | A-Award | A | Common Stock, $.0001 par value | 18,500 | 0.00 | — | 45,651 | D | ↗ |
| 2025-12-31 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $.0001 par value | 5,000 | 1.03 | 5.2K | 291,421 | D | ↗ |
| 2025-12-23 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $.0001 par value | 5,000 | 1.02 | 5.1K | 286,421 | D | ↗ |
| 2025-11-21 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $.0001 par value | 5,000 | 1.14 | 5.7K | 281,421 | D | ↗ |
| 2025-11-18 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $.0001 par value | 5,000 | 1.27 | 6.4K | 276,421 | D | ↗ |
| 2025-09-11 | Lockshin Curtis | Director | A-Award | A | Common Stock, $.0001 par value | 16,200 | 0.00 | — | 18,555 | D | ↗ |
| 2025-09-11 | Freeman Jonathan E | Director | A-Award | A | Common Stock, $.0001 par value | 14,700 | 0.00 | — | 16,055 | D | ↗ |
| 2025-09-11 | Ferrara Robert L | Director | A-Award | A | Common Stock, $.0001 par value | 23,100 | 0.00 | — | 38,766 | D | ↗ |
| 2025-09-11 | Deming David H | Director | A-Award | A | Common Stock, $.0001 par value | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2025-09-11 | Carson Lisa Cabott | Officer | A-Award | A | Common Stock, $.0001 par value | 47,000 | 0.00 | — | 47,000 | D | ↗ |
| 2025-09-11 | Bitterman Robert J | Director / Officer | A-Award | A | Common Stock, $.0001 par value | 250,000 | 0.00 | — | 271,421 | D | ↗ |
| 2025-09-11 | BRADFORD PATRICIA A | Director | A-Award | A | Common Stock, $.0001 par value | 18,800 | 0.00 | — | 27,151 | D | ↗ |
| 2025-06-10 | Ferrara Robert L | Director | P-Purchase | A | Common stock, $0.0001 par value | 2,500 | 2.42 | 6.0K | 15,666 | D | ↗ |
| 2025-06-10 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 2,000 | 2.42 | 4.8K | 27,149 | D | ↗ |
| 2025-06-09 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 1,500 | 2.75 | 4.1K | 25,149 | D | ↗ |
| 2025-06-06 | Carson Lisa Cabott | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-22 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 1,200 | 1.78 | 2.1K | 23,649 | D | ↗ |
| 2025-05-21 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 3,000 | 1.77 | 5.3K | 22,449 | D | ↗ |
| 2025-05-20 | Ferrara Robert L | Director | P-Purchase | A | Common stock, $0.0001 par value | 2,500 | 1.82 | 4.6K | 13,166 | D | ↗ |
| 2025-02-19 | Deming David H | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-11 | Lockshin Curtis | Director | A-Award | A | Common Stock, $0.0001 par value | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2024-09-11 | Infarinato Robert M. | Officer | A-Award | A | Common Stock, $0.0001 Par Value | 3,000 | 0.00 | — | 11,000 | — | ↗ |
| 2024-09-11 | Freeman Jonathan E | Director | A-Award | A | Common Stock, $0.0001 par value | 1,000 | 0.00 | — | 1,000 | — | ↗ |
| 2024-09-11 | Ferrara Robert L | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2024-09-11 | Bitterman Robert J | Director / Officer | A-Award | A | Common Stock, $0.0001 par value | 15,500 | 0.00 | — | 17,832 | — | ↗ |
| 2024-09-11 | BRADFORD PATRICIA A | Director | A-Award | A | Common Stock, $0.0001 par value | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2024-08-13 | Infarinato Robert M. | Officer | A-Award | A | Common stock, $0.0001 par value | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2024-08-01 | Infarinato Robert M. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-07 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,000 | 0.74 | 740.00 | 20,990 | — | ↗ |
| 2024-06-06 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,000 | 0.75 | 750.00 | 19,990 | — | ↗ |
| 2024-03-01 | Kontulis Caitlin | Officer | F-InKind | D | Common stock, $0.0001 par value | 335 | 0.96 | 320.93 | 10,643 | — | ↗ |
| 2024-02-26 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,500 | 0.91 | 2.3K | 18,990 | — | ↗ |
| 2024-02-20 | Bitterman Robert J | Director / Officer | F-InKind | D | Common stock, $0.0001 par value | 1,804 | 0.76 | 1.4K | 16,490 | — | ↗ |
| 2024-02-17 | Kontulis Caitlin | Officer | F-InKind | D | Common stock, $0.0001 par value | 523 | 0.66 | 345.18 | 10,978 | — | ↗ |
| 2024-02-15 | Kontulis Caitlin | Officer | F-InKind | D | Common stock, $0.0001 par value | 658 | 0.65 | 427.70 | 11,501 | — | ↗ |
| 2023-10-01 | Bitterman Robert J | Director / Officer | F-InKind | D | Common stock, $0.0001 par value | 917 | 1.51 | 1.4K | 18,294 | — | ↗ |
| 2023-07-01 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,000 | 2.84 | 2.8K | 19,211 | — | ↗ |
| 2023-06-30 | Bitterman Robert J | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,000 | 2.88 | 2.9K | 18,211 | — | ↗ |
| 2023-06-14 | Ferrara Robert L | Director | P-Purchase | A | Common stock, $0.0001 par value | 2,000 | 3.10 | 6.2K | 6,000 | — | ↗ |
| 2023-03-01 | Kontulis Caitlin | Officer | F-InKind | D | Common stock, $0.0001 par value | 335 | 5.49 | 1.8K | 12,159 | — | ↗ |
| 2023-02-20 | Bitterman Robert J | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 11,000 | 0.00 | — | 17,211 | — | ↗ |
| 2023-02-17 | Lockshin Curtis | Director | A-Award | A | Common stock, $0.0001 par value | 1,500 | 0.00 | — | 3,197 | — | ↗ |
| 2023-02-17 | Kontulis Caitlin | Officer | A-Award | A | Common stock, $0.0001 par value | 4,500 | 0.00 | — | 12,494 | — | ↗ |
| 2023-02-17 | Freeman Jonathan E | Director | A-Award | A | Common stock, $0.0001 par value | 1,500 | 0.00 | — | 3,197 | — | ↗ |
| 2023-02-17 | Ferrara Robert L | Director | A-Award | A | Common stock, $0.0001 par value | 1,500 | 0.00 | — | 4,000 | — | ↗ |
| 2023-02-17 | CAUWENBERGH GEERT | Director | A-Award | A | Common stock, $0.0001 par value | 1,500 | 0.00 | — | 4,235 | — | ↗ |
| 2023-02-17 | BRADFORD PATRICIA A | Director | A-Award | A | Common stock, $0.0001 par value | 1,500 | 0.00 | — | 3,167 | — | ↗ |
| 2023-02-15 | Kontulis Caitlin | Officer | F-InKind | D | Common stock, $0.0001 par value | 657 | 5.20 | 3.4K | 7,994 | — | ↗ |
| 2022-12-14 | Bitterman Robert J | Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,000 | 0.39 | 780.00 | 74,541 | — | ↗ |
| 2022-12-07 | Bitterman Robert J | Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,000 | 0.39 | 780.00 | 72,541 | — | ↗ |
| 2022-12-05 | Bitterman Robert J | Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,000 | 0.43 | 860.00 | 70,541 | — | ↗ |
| 2022-12-02 | Ferrara Robert L | Director | P-Purchase | A | Common stock, $0.0001 par value | 5,000 | 0.41 | 2.0K | 30,000 | — | ↗ |
| 2022-11-29 | Bitterman Robert J | Officer | P-Purchase | A | Common stock, $0.0001 par value | 215 | 0.40 | 86.00 | 68,541 | — | ↗ |
| 2022-11-25 | Bitterman Robert J | Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,500 | 0.42 | 1.1K | 68,326 | — | ↗ |
| 2022-11-23 | Ferrara Robert L | Director | P-Purchase | A | Common stock, $0.0001 par value | 2,000 | 0.41 | 819.80 | 25,000 | — | ↗ |
| 2022-11-16 | Bitterman Robert J | Officer | P-Purchase | A | Series D Preferred Stock, $0.0001 par value | 1 | 1,750.00 | 1.8K | 1 | — | ↗ |
| 2022-10-01 | Bitterman Robert J | Director | A-Award | A | Common stock, $0.0001 par value | 40,000 | 0.00 | — | 65,826 | — | ↗ |
| 2022-08-09 | BRADFORD PATRICIA A | Director | A-Award | A | Common stock, $0.0001 par value | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-04-27 | BRADFORD PATRICIA A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-01 | Kontulis Caitlin | Officer | F-InKind | D | Common stock, $0.0001 par value | 4,011 | 0.82 | 3.3K | 103,815 | — | ↗ |
| 2022-03-01 | Dispersyn Gerrit | Director / Officer | F-InKind | D | Common stock, $0.0001 par value | 8,954 | 0.82 | 7.4K | 212,327 | — | ↗ |
| 2022-02-15 | Lockshin Curtis | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 20,366 | — | ↗ |
| 2022-02-15 | Kontulis Caitlin | Officer | A-Award | A | Common stock, $0.0001 par value | 68,000 | 0.00 | — | 107,826 | — | ↗ |
| 2022-02-15 | Freeman Jonathan E | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 20,364 | — | ↗ |
| 2022-02-15 | Ferrara Robert L | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 23,000 | — | ↗ |
| 2022-02-15 | Dorman H. Paul | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 20,370 | — | ↗ |
| 2022-02-15 | Dispersyn Gerrit | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 126,000 | 0.00 | — | 221,281 | — | ↗ |
| 2022-02-15 | CAUWENBERGH GEERT | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 32,822 | — | ↗ |
| 2022-02-15 | Bitterman Robert J | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 25,826 | — | ↗ |
| 2021-08-16 | Dispersyn Gerrit | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 6,000 | 1.63 | 9.8K | 95,281 | — | ↗ |
| 2021-03-04 | Dispersyn Gerrit | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,953 | 2.56 | 5.0K | 89,281 | — | ↗ |
| 2021-03-03 | Ferrara Robert L | Director | P-Purchase | A | Common stock, $0.0001 par value | 682 | 3.15 | 2.1K | 13,000 | — | ↗ |
| 2021-03-03 | Dispersyn Gerrit | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,500 | 3.03 | 7.6K | 87,328 | — | ↗ |
| 2021-03-01 | Lockshin Curtis | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 10,366 | — | ↗ |
| 2021-03-01 | Kontulis Caitlin | Officer | A-Award | A | Common stock, $0.0001 par value | 34,600 | 0.00 | — | 39,826 | — | ↗ |
| 2021-03-01 | Freeman Jonathan E | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 10,364 | — | ↗ |
| 2021-03-01 | Ferrara Robert L | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 12,318 | — | ↗ |
| 2021-03-01 | Dorman H. Paul | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 10,370 | — | ↗ |
| 2021-03-01 | Dispersyn Gerrit | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 68,450 | 0.00 | — | 84,828 | — | ↗ |
| 2021-03-01 | CAUWENBERGH GEERT | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 22,822 | — | ↗ |
| 2021-03-01 | Bitterman Robert J | Director | A-Award | A | Common stock, $0.0001 par value | 10,000 | 0.00 | — | 15,826 | — | ↗ |
| 2020-08-19 | Dispersyn Gerrit | Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,000 | 2.50 | 5.0K | 16,377 | — | ↗ |
| 2020-03-01 | Dispersyn Gerrit | Officer | F-InKind | D | Common stock, $0.0001 par value | 673 | 2.93 | 2.0K | 14,628 | — | ↗ |
| 2019-11-18 | Kontulis Caitlin | Officer | A-Award | A | Common stock, $0.0001 par value | 237,500 | 0.10 | 23.8K | 279,030 | — | ↗ |
| 2019-11-18 | Ferrara Robert L | Director | A-Award | A | Common stock, $0.0001 par value | 127,500 | 0.10 | 12.8K | 127,500 | — | ↗ |
| 2019-11-18 | Dispersyn Gerrit | Officer | A-Award | A | Common stock, $0.0001 par value | 350,000 | 0.10 | 35.0K | 827,817 | — | ↗ |
| 2019-11-18 | CAUWENBERGH GEERT | Director | A-Award | A | Common stock, $0.0001 par value | 225,000 | 0.10 | 22.5K | 704,841 | — | ↗ |
| 2019-11-18 | Bitterman Robert J | Director | A-Award | A | Common stock, $0.0001 par value | 300,000 | 0.10 | 30.0K | 320,440 | — | ↗ |
| 2019-10-24 | Ferrara Robert L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-01 | Kontulis Caitlin | Officer | F-InKind | D | Common stock, $0.0001 par value | 749 | 0.40 | 301.85 | 41,530 | — | ↗ |
| 2019-08-01 | Dispersyn Gerrit | Officer | F-InKind | D | Common stock, $0.0001 par value | 1,236 | 0.40 | 498.11 | 477,817 | — | ↗ |
| 2019-08-01 | CAUWENBERGH GEERT | Director | F-InKind | D | Common stock, $0.0001 par value | 1,751 | 0.40 | 705.65 | 479,841 | — | ↗ |
| 2019-04-22 | Barrett John A | Officer | A-Award | A | Common stock, $0.0001 par value | 222,991 | 0.00 | — | 222,991 | — | ↗ |
| 2019-03-01 | Dispersyn Gerrit | Officer | A-Award | A | Common Stock | 407,703 | 0.00 | — | 479,053 | — | ↗ |
| 2019-02-28 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 152,415 | 0.38 | 57.9K | 481,592 | — | ↗ |
| 2019-02-15 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 22,279 | 0.36 | 8.1K | 329,177 | — | ↗ |
| 2019-02-13 | Lockshin Curtis | Director | A-Award | A | Common stock | 10,000 | 0.00 | — | 20,130 | — | ↗ |
| 2019-02-13 | Kontulis Caitlin | Officer | A-Award | A | Common stock | 27,000 | 0.00 | — | 40,214 | — | ↗ |
| 2019-02-13 | Freeman Jonathan E | Director | A-Award | A | Common stock | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2019-02-13 | Dorman H. Paul | Director | A-Award | A | Common stock | 10,000 | 0.00 | — | 20,375 | — | ↗ |
| 2019-02-13 | Dispersyn Gerrit | Officer | A-Award | A | Common stock | 55,000 | 0.00 | — | 71,350 | — | ↗ |
| 2019-02-13 | Brownlie Keith L | Director | A-Award | A | Common stock | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2019-02-13 | Bitterman Robert J | Director | A-Award | A | Common stock | 10,000 | 0.00 | — | 20,440 | — | ↗ |
| 2019-02-01 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common Stock, $0.0001 par value | 21,470 | 0.38 | 8.1K | 306,898 | — | ↗ |
| 2019-01-18 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 23,729 | 0.34 | 8.1K | 285,428 | — | ↗ |
| 2019-01-04 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 23,139 | 0.35 | 8.1K | 261,699 | — | ↗ |
| 2018-12-21 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 27,445 | 0.30 | 8.1K | 238,560 | — | ↗ |
| 2018-12-07 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 21,882 | 0.37 | 8.1K | 211,115 | — | ↗ |
| 2018-11-23 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 25,941 | 0.31 | 8.1K | 189,233 | — | ↗ |
| 2018-11-09 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 18,698 | 0.43 | 8.1K | 163,292 | — | ↗ |
| 2018-10-26 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 18,519 | 0.44 | 8.1K | 144,594 | — | ↗ |
| 2018-10-12 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 17,230 | 0.47 | 8.1K | 126,075 | — | ↗ |
| 2018-09-28 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 73,587 | 1.17 | 86.1K | 108,845 | — | ↗ |
| 2018-08-01 | Lockshin Curtis | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,130 | — | ↗ |
| 2018-08-01 | Kontulis Caitlin | Officer | A-Award | A | Stock option (right to buy) | 10,500 | 1.79 | 18.8K | 10,500 | — | ↗ |
| 2018-08-01 | Freeman Jonathan E | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-01 | Dorman H. Paul | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,375 | — | ↗ |
| 2018-08-01 | Dispersyn Gerrit | Officer | A-Award | A | Stock option (right to buy) | 16,000 | 1.79 | 28.6K | 16,000 | — | ↗ |
| 2018-08-01 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common Stock | 21,000 | 0.00 | — | 35,258 | — | ↗ |
| 2018-08-01 | Brownlie Keith L | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-01 | Bitterman Robert J | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,440 | — | ↗ |
| 2017-10-02 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 7,100 | 0.45 | 3.2K | 142,583 | — | ↗ |
| 2017-09-07 | Eliseev Alexey | Officer | S-Sale | D | Common stock, par value $0.0001 | 58,712 | 0.53 | 31.0K | 950,312 | — | ↗ |
| 2017-09-06 | Eliseev Alexey | Officer | S-Sale | D | Common stock, par value $0.0001 | 91,907 | 0.54 | 49.3K | 1,009,024 | — | ↗ |
| 2017-09-05 | Eliseev Alexey | Officer | S-Sale | D | Common stock, par value $0.0001 | 26,181 | 0.56 | 14.6K | 1,100,931 | — | ↗ |
| 2017-09-01 | Eliseev Alexey | Officer | S-Sale | D | Common stock, $0.0001 par value | 23,200 | 0.57 | 13.2K | 1,127,112 | — | ↗ |
| 2017-08-24 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 739 | 0.56 | 413.84 | 132,583 | — | ↗ |
| 2017-06-23 | Dispersyn Gerrit | Officer | P-Purchase | A | Common stock, $0.0001 par value | 3,500 | 0.62 | 2.2K | 3,500 | — | ↗ |
| 2017-06-22 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 5,000 | 0.62 | 3.1K | 122,583 | — | ↗ |
| 2017-06-09 | Eliseev Alexey | Officer | C-Conversion | A | Common stock, $0.0001 par value | 332,499 | 0.00 | — | 1,150,312 | — | ↗ |
| 2017-06-06 | Freeman Jonathan E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-04-26 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 10,000 | 0.65 | 6.5K | 112,583 | — | ↗ |
| 2017-04-24 | Dispersyn Gerrit | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-04-12 | Eliseev Alexey | Officer | — | D | Series C Convertible Preferred Stock, $0.0001 par value | 332,499 | 0.00 | — | 0 | — | ↗ |
| 2017-03-17 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 15 | 0.77 | 11.48 | 102,583 | — | ↗ |
| 2017-02-17 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,917 | 0.70 | 2.0K | 92,583 | — | ↗ |
| 2017-02-08 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 10,000 | 0.69 | 6.9K | 82,583 | — | ↗ |
| 2017-02-01 | Pavco Pamela | Officer | A-Award | A | Stock option (right to buy) | 7,000 | 0.63 | 4.4K | 7,000 | — | ↗ |
| 2017-02-01 | Lockshin Curtis | Director | A-Award | A | Stock option (right to buy) | 2,000 | 0.63 | 1.3K | 2,000 | — | ↗ |
| 2017-02-01 | Kontulis Caitlin | Officer | A-Award | A | Stock option (right to buy) | 2,500 | 0.63 | 1.6K | 2,500 | — | ↗ |
| 2017-02-01 | Dorman H. Paul | Director | A-Award | A | Stock option (right to buy) | 2,000 | 0.63 | 1.3K | 2,000 | — | ↗ |
| 2017-02-01 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Stock option (right to buy) | 13,000 | 0.63 | 8.2K | 13,000 | — | ↗ |
| 2017-02-01 | Brownlie Keith L | Director | A-Award | A | Stock option (right to buy) | 2,000 | 0.63 | 1.3K | 2,000 | — | ↗ |
| 2017-02-01 | Bitterman Robert J | Director | A-Award | A | Stock option (right to buy) | 2,000 | 0.63 | 1.3K | 2,000 | — | ↗ |
| 2017-01-25 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 9,700 | 0.70 | 6.8K | 72,583 | — | ↗ |
| 2017-01-19 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 600 | 0.69 | 416.94 | 62,583 | — | ↗ |
| 2017-01-06 | Eliseev Alexey | Officer | — | D | Series C Convertible Preferred Stock, $0.0001 par value | 331,713 | 0.00 | — | 0 | — | ↗ |
| 2016-12-30 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 2,000 | 0.73 | 1.5K | 52,583 | — | ↗ |
| 2016-12-23 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 3,000 | 0.72 | 2.2K | 4,500 | — | ↗ |
| 2016-12-22 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 3,000 | 0.75 | 2.2K | 53,583 | — | ↗ |
| 2016-12-16 | Pavco Pamela | Officer | A-Award | A | Common stock, $0.0001 par value | 11,111 | 0.90 | 10.0K | 17,173 | — | ↗ |
| 2016-12-16 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 33,333 | 0.90 | 30.0K | 50,583 | — | ↗ |
| 2016-02-10 | Pavco Pamela | Officer | A-Award | A | Stock option (right to buy) | 66,000 | 0.29 | 18.9K | 66,000 | — | ↗ |
| 2016-02-10 | Lockshin Curtis | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.29 | 4.8K | 16,666 | — | ↗ |
| 2016-02-10 | Kontulis Caitlin | Officer | A-Award | A | Stock option (right to buy) | 20,000 | 0.29 | 5.7K | 20,000 | — | ↗ |
| 2016-02-10 | Dorman H. Paul | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.29 | 4.8K | 16,666 | — | ↗ |
| 2016-02-10 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Stock option (right to buy) | 133,000 | 0.29 | 38.0K | 133,000 | — | ↗ |
| 2016-02-10 | Brownlie Keith L | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.29 | 4.8K | 16,666 | — | ↗ |
| 2016-02-10 | Bitterman Robert J | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.29 | 4.8K | 16,666 | — | ↗ |
| 2015-06-22 | CAUWENBERGH GEERT | Director / Officer | X-InTheMoney | A | Common stock, $0.0001 par value | 35,000 | 0.46 | 15.9K | 172,500 | — | ↗ |
| 2015-06-02 | Pavco Pamela | Officer | A-Award | A | Common stock purchase warrant | 6,250 | 0.52 | 3.3K | 6,250 | — | ↗ |
| 2015-06-02 | Lockshin Curtis | Director | A-Award | A | Common stock warrant | 6,000 | 0.52 | 3.1K | 6,000 | — | ↗ |
| 2015-06-02 | Dorman H. Paul | Director | A-Award | A | Common stock warrant | 18,750 | 0.52 | 9.8K | 18,750 | — | ↗ |
| 2015-06-02 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Common stock, $0.0001 par value | 70,000 | 0.40 | 28.0K | 137,500 | — | ↗ |
| 2015-06-02 | Bitterman Robert J | Director | A-Award | A | Common stock warrants | 18,750 | 0.52 | 9.8K | 18,750 | — | ↗ |
| 2015-06-01 | Pavco Pamela | Officer | A-Award | A | Stock option (right to buy) | 66,000 | 0.38 | 25.1K | 66,000 | — | ↗ |
| 2015-06-01 | Lockshin Curtis | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.38 | 6.3K | 16,666 | — | ↗ |
| 2015-06-01 | Kontulis Caitlin | Officer | A-Award | A | Stock option (right to buy) | 10,000 | 0.38 | 3.8K | 10,000 | — | ↗ |
| 2015-06-01 | Dorman H. Paul | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.38 | 6.3K | 16,666 | — | ↗ |
| 2015-06-01 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Stock option (right to buy) | 133,000 | 0.38 | 50.5K | 133,000 | — | ↗ |
| 2015-06-01 | Brownlie Keith L | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.38 | 6.3K | 16,666 | — | ↗ |
| 2015-06-01 | Bitterman Robert J | Director | A-Award | A | Stock option (right to buy) | 16,666 | 0.38 | 6.3K | 16,666 | — | ↗ |
| 2015-04-02 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 5,000 | 0.72 | 3.6K | 67,500 | — | ↗ |
| 2015-02-17 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 4,000 | 1.17 | 4.7K | 62,500 | — | ↗ |
| 2015-02-10 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,156 | 1.25 | 1.4K | 58,500 | — | ↗ |
| 2015-01-22 | Bitterman Robert J | Director | P-Purchase | A | Common stock, $0.0001 par value | 1,853 | 1.19 | 2.2K | 6,500 | — | ↗ |
| 2015-01-20 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 10,000 | 1.03 | 10.3K | 56,500 | — | ↗ |
| 2014-12-30 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 500 | 1.59 | 794.65 | 46,500 | — | ↗ |
| 2014-10-13 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 3,000 | 1.68 | 5.0K | 44,000 | — | ↗ |
| 2014-09-19 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 | 4,500 | 2.20 | 9.9K | 4,500 | — | ↗ |
| 2014-09-16 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 5,000 | 2.08 | 10.4K | 46,000 | — | ↗ |
| 2014-09-15 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 2,000 | 2.19 | 4.4K | 41,000 | — | ↗ |
| 2014-07-31 | Advanced RNA Technologies, LLC | — | P-Purchase | A | Common Stock, $0.0001 par value | 400 | 2.48 | 992.00 | 1,221,723 | — | ↗ |
| 2014-07-15 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 1,000 | 2.50 | 2.5K | 31,000 | — | ↗ |
| 2014-07-09 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,400 | 2.57 | 3.6K | 30,000 | — | ↗ |
| 2014-07-02 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,000 | 2.86 | 2.9K | 28,300 | — | ↗ |
| 2014-06-25 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 500 | 3.01 | 1.5K | 26,600 | — | ↗ |
| 2014-06-19 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 800 | 2.96 | 2.4K | 26,100 | — | ↗ |
| 2014-06-09 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 200 | 3.05 | 610.00 | 23,300 | — | ↗ |
| 2014-06-04 | CAUWENBERGH GEERT | Director / Officer | P-Purchase | A | Common stock, $0.0001 par value | 1,000 | 2.97 | 3.0K | 23,100 | — | ↗ |
| 2014-06-02 | Pavco Pamela | Officer | A-Award | A | Stock Option (right to buy) | 66,000 | 2.85 | 188.1K | 66,000 | — | ↗ |
| 2014-06-02 | Lockshin Curtis | Director | A-Award | A | Stock Option (right to buy) | 16,666 | 2.85 | 47.5K | 16,666 | — | ↗ |
| 2014-06-02 | Kontulis Caitlin | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2014-06-02 | Dorman H. Paul | Director | A-Award | A | Stock Option (right to buy) | 16,666 | 2.85 | 47.5K | 16,666 | — | ↗ |
| 2014-06-02 | CAUWENBERGH GEERT | Director / Officer | A-Award | A | Stock Option (right to buy) | 133,000 | 2.85 | 379.1K | 133,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
11.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Robert J. Bitterman President and Chief Executive Officer | 342.6K | — | 43.2K | — | — | 1.2K | 387.0K | 11.17% | ↗ |
| 2 | 2024 | Robert M. Infarinato Vice President and Chief Financial Officer | 75.5K | — | 29.3K | — | — | 414.00 | 105.2K | 27.88% | ↗ |
| 3 | 2023 | Robert J. Bitterman President and Chief Executive Officer | 380.0K | — | 57.6K | — | — | 252.00 | 437.9K | 13.16% | ↗ |
| 4 | 2022 | Gerrit Dispersyn, Dr. Med. Sc. Former President and Chief Executive Officer | 178.5K | — | 108.5K | — | — | 202.7K | 489.8K | 22.16% | ↗ |
| 5 | 2022 | Robert J. Bitterman President and Chief Executive Officer | 77.9K | — | 31.5K | — | — | 31.00 | 109.4K | 28.77% | ↗ |
| 6 | 2022 | Geert Cauwenbergh, Dr. Med. Sc. Former interim Principal Executive and Financial Officer | 68.8K | — | 8.6K | — | — | — | 77.4K | 11.13% | ↗ |
| 7 | 2021 | Gerrit Dispersyn, Dr. Med. Sc. Former President and Chief Executive Officer | 403.4K | — | 210.8K | — | 136.7K | 575.00 | 751.5K | 28.05% | ↗ |
| 8 | 2021 | Gerrit Dispersyn, Dr. Med. Sc. Former President and Chief Executive Officer, Director | 403.4K | — | 210.8K | — | 136.7K | 575.00 | 751.5K | 28.05% | ↗ |
| 9 | 2021 | Robert J. Bitterman President and Chief Executive Officer | 47.5K | — | 30.8K | — | — | — | 78.3K | 39.34% | ↗ |
| 10 | 2021 | Geert Cauwenbergh, Dr. Med. Sc. Former interim Principal Executive and Financial Officer | 27.5K | — | 30.8K | — | — | — | 58.3K | 52.83% | ↗ |
| 11 | 2020 | Gerrit Dispersyn, Dr. Med. Sc. President and Chief Executive Officer | 386.6K | — | — | — | 196.0K | 528.00 | 583.1K | 0.00% | ↗ |
| 12 | 2020 | Gerrit Dispersyn, Dr. Med. Sc. Former President and Chief Executive Officer, Director | 386.6K | — | — | — | 196.0K | 528.00 | 583.1K | 0.00% | ↗ |
| 13 | 2019 | Gerrit Dispersyn, Dr. Med. Sc. President and Chief Executive Officer | 372.3K | — | 117.7K | — | 168.9K | 534.00 | 659.4K | 17.84% | ↗ |
| 14 | 2019 | John Barrett, Ph.D. Former Chief Development Officer | 156.7K | — | 103.7K | — | — | 161.00 | 260.6K | 39.79% | ↗ |
| 15 | 2019 | Geert Cauwenbergh, Dr. Med. Sc. Former Chief Executive Officer | 131.7K | — | — | — | — | 152.00 | 131.8K | 0.00% | ↗ |
| 16 | 2018 | Geert Cauwenbergh, Dr. Med. Sc. Former Chief Executive Officer | 420.4K | — | 37.6K | 36.1K | 115.8K | 606.00 | 610.4K | 12.07% | ↗ |
| 17 | 2018 | Gerrit Dispersyn, Dr. Med. Sc. President and Chief Executive Officer | 315.6K | — | 28.6K | 27.5K | 52.8K | 454.00 | 425.0K | 13.21% | ↗ |
| 18 | 2017 | Geert Cauwenbergh, Dr. Med. Sc. Former Chief Executive Officer | 416.0K | — | — | 5.9K | 156.0K | 599.00 | 578.5K | 1.02% | ↗ |
| 19 | 2017 | Geert Cauwenbergh, Dr. Med. Sc. President, Chief Executive Officer and acting Chief Financial Officer | 416.0K | — | — | 5.9K | — | 599.00 | 422.5K | 1.40% | ↗ |
| 20 | 2017 | Alexey Eliseev, Ph.D. Former Chief Business Officer | 215.7K | — | — | 91.0K | — | 75.3K | 382.0K | 23.83% | ↗ |
| 21 | 2017 | Gerrit Dispersyn, Dr. Med. Sc. President and Chief Executive Officer | 186.3K | — | — | 44.6K | 44.1K | 275.00 | 275.3K | 16.19% | ↗ |
| 22 | 2017 | Gerrit Dispersyn, Dr. Med. Sc. Chief Development Officer | 186.3K | — | — | 44.6K | — | 275.00 | 231.2K | 19.27% | ↗ |
| 23 | 2017 | Pamela Pavco, Ph.D. Former Chief Development Officer | 196.5K | — | — | 3.2K | — | 228.00 | 199.9K | 1.58% | ↗ |
| 24 | 2016 | Geert Cauwenbergh, Dr. Med. Sc. President, Chief Executive Officer and acting Chief Financial Officer | 413.7K | — | — | 26.6K | 197.6K | 624.00 | 638.5K | 4.17% | ↗ |
| 25 | 2016 | Pamela Pavco, Ph.D. Former Chief Development Officer | 377.5K | — | — | 13.2K | 108.2K | 585.00 | 499.5K | 2.64% | ↗ |
| 26 | 2016 | Pamela Pavco, Ph.D. Chief Development Officer | 377.5K | — | — | 13.2K | 108.2K | 585.00 | 499.5K | 2.64% | ↗ |
| 27 | 2015 | Geert Cauwenbergh, Dr. Med. Sc. President, Chief Executive Officer and acting Chief Financial Officer | 398.4K | — | — | 37.2K | 190.0K | 300.00 | 625.9K | 5.95% | ↗ |
| 28 | 2015 | Pamela Pavco, Ph.D. Chief Development Officer | 363.8K | — | — | 18.5K | 104.0K | 300.00 | 486.6K | 3.80% | ↗ |
| 29 | 2015 | Geert Cauwenbergh, Dr. Med. Sc. | — | — | — | — | — | — | — | — | ↗ |
| 30 | 2015 | Keith L. Brownlie | — | — | — | — | — | — | — | — | ↗ |
| 31 | 2015 | Curtis A. Lockshin, Ph.D. | — | — | — | — | — | — | — | — | ↗ |
| 32 | 2015 | Robert J. Bitterman | — | — | — | — | — | — | — | — | ↗ |
| 33 | 2015 | H. Paul Dorman | — | — | — | — | — | — | — | — | ↗ |
| 34 | 2014 | Geert Cauwenbergh, Dr. Med. Sc. President, Chief Executive Officer and acting Chief Financial Officer | 381.3K | — | — | 305.9K | 114.0K | 552.00 | 801.7K | 38.16% | ↗ |
| 35 | 2014 | Pamela Pavco, Ph.D. Chief Development Officer | 350.6K | — | — | 150.5K | 63.0K | 300.00 | 564.4K | 26.66% | ↗ |
| 36 | 2014 | Curtis A. Lockshin, Ph.D. | — | — | — | — | — | — | — | — | ↗ |
| 37 | 2014 | Geert Cauwenbergh, Dr. Med. Sc. | — | — | — | — | — | — | — | — | ↗ |
| 38 | 2014 | Keith L. Brownlie | — | — | — | — | — | — | — | — | ↗ |
| 39 | 2014 | Robert J. Bitterman | — | — | — | — | — | — | — | — | ↗ |
| 40 | 2014 | H. Paul Dorman | — | — | — | — | — | — | — | — | ↗ |
| 41 | 2013 | Robert J. Bitterman | — | — | — | — | — | — | — | — | ↗ |
| 42 | 2013 | Curtis A. Lockshin, Ph.D. | — | — | — | — | — | — | — | — | ↗ |
| 43 | 2013 | Geert Cauwenbergh, Dr. Med. Sc. | — | — | — | — | — | — | — | — | ↗ |
| 44 | 2013 | Keith L. Brownlie | — | — | — | — | — | — | — | — | ↗ |
| 45 | 2013 | H. Paul Dorman | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert J. Bitterman | President, Chief Executive Officer & Chairman | 579.4K | male |
| Lisa Carson | CFO, Principal Accounting Officer and VP of Finance & Administration | 371.4K | female |
| Jennifer Phillips | Senior Vice President of Regulatory & Corporate Affairs | — | — |
| Linda Mahoney | Senior Vice President of Development | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
